Le Lézard
Classified in: Health, Covid-19 virus
Subject: AVO

NEW AGREEMENT JEOPARDIZES VIRTUAL CARE ACCESS FOR ONTARIO FAMILIES


New campaign launched to ensure equitable virtual health care for all families

TORONTO, April 4, 2022 /CNW/ - KixCare, a pediatric virtual care platform, has launched the SaveVirtualCare.ca campaign to protect Ontario families from losing access to convenient and effective virtual care that have been vital throughout the COVID-19 pandemic.

"Publicly funded virtual care during the pandemic has been a silver lining that has provided Ontario families with equitable and timely access to pediatricians to address their children's health concerns. That access should continue," said Daniel Warner, co-founder and CEO of KixCare. "In a health care system already exceeding its capacity, we've helped thousands of families meet with a pediatrician in a secure, caring way. This meant families could avoid waiting hours for urgent care in an emergency room or walk-in clinic."

The advocacy campaign is in response to the newly ratified Physician Services Agreement (PSA) between the Ontario Medical Association and the Ministry of Health, where the new agreement jeopardizes virtual care access for nearly 1.5 million Ontarians who do not have a primary care provider or those who are unable to access their provider in a timely manner.

"Many pediatricians are concerned about virtual care funding changes in this new agreement and its impact on underserved families. It will negatively impact families already at a disadvantage accessing healthcare services," said Dr. Harley Eisman, KixCare's co-founder and Chief Medical Officer. "We're working with Ontario families and pediatricians to send a message to their local MPP that virtual care is a fundamental necessity in delivering timely access to health care all Ontario families deserve."

For more information visit www.savevirtualcare.ca

Quick Facts

 

SOURCE KixCare


These press releases may also interest you

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...

3 jui 2024
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...

3 jui 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...

3 jui 2024
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...



News published on and distributed by: